Take a look at our previous reports:

25. Deferred income

The movement in the non-current and current deferred income is detailed in the table below.

(thousands of €)

Total

Gilead collaboration agreement for filgotinib

Gilead collaboration agreement for drug discovery platform(1)

Deferred income related to contracts in our fee-for-service segment

Other deferred income (grants)

On 1 January 2020

3,000,646

780,261

2,220,013

362

10

 

 

 

 

 

 

Upfront consideration

160,000

160,000

 

 

 

Milestones received

90,192

90,192

 

 

 

Significant financing component(2)

16,278

16,278

 

 

 

 

 

 

 

 

 

Revenue recognition of upfront

(411,417)

(181,816)

(229,601)

 

 

Revenue recognition of milestones

(46,261)

(46,261)

 

 

 

 

 

 

 

 

 

Other movements

(305)

 

 

(362)

57

 

 

 

 

 

 

On 31 December 2020

2,809,133

818,654

1,990,412

-

67

 

 

 

 

 

 

 

 

 

 

 

 

Upfront consideration

12,643

12,643

 

 

 

Significant financing component(2)

9,289

9,289

 

 

 

 

 

 

 

 

 

Revenue recognition of upfront

(433,884)

(203,301)

(230,582)

 

 

Revenue recognition of milestones

(32,408)

(32,408)

 

 

 

 

 

 

 

 

 

Other movements

(67)

 

 

 

(67)

 

 

 

 

 

 

On 31 December 2021

2,364,701

604,875

1,759,828

-

-

(1)

The upfront received and the outstanding balance at 31 December 2021 and at 31 December 2020 comprise the issuance liabilities for the warrants and the upfront payment allocated to the drug discovery platform.

(2)

With regard to the additional consideration received for the extended cost sharing for filgotinib, we assume the existence of a significant financing component reflecting the time value of money on the estimated recognition period.

We refer to note 6 for a detail of the allocation of the transaction price of our collaboration with Gilead.